PXTNX Performance — PIMCO RAE PLUS Fund, Class I-3
Data updated: 2026-08-31
PXTNX returned +19.49% year to date and +36.10% over one year to Jun 2026. Annualised returns are +22.32% over 3 years and +12.71% over 5 years. The fund beat its US Large Value category average: $100 invested three years ago grew to $183, against $158 for the category, and to $136 over one year, against $121. Volatility over the past three years was 13.77% a year. In the 12 months to Jun 2026 the fund lost a net $30.9M, and assets reached $1.27B.
PXTNX Growth of $100
What $100 invested in PIMCO RAE PLUS Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Large Value category average over the same months.
| Period | PXTNX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $136 | $121 |
| 3 years (Jul 2023 – Jun 2026) | $183 | $158 |
| 5 years (Jul 2021 – Jun 2026) | $182 | $165 |
| Since data start (Jul 2019 – Jun 2026) | $254 | $223 |
PXTNX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +19.49% |
| 1 year | +36.10% |
| 3 years (annualised) | +22.32% |
| 5 years (annualised) | +12.71% |
PXTNX Annual Returns
Calendar-year total returns of PIMCO RAE PLUS Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +19.49% |
| 2025 | +21.26% |
| 2024 | +11.41% |
| 2023 | +18.31% |
| 2022 | −8.82% |
| 2021 | +27.29% |
| 2020 | +4.36% |
| 2019 (Jul–Dec) | +10.01% |
PXTNX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.4% | +3.5% | −1.8% | +7.0% | +4.8% | +0.4% | — | — | — | — | — | — |
| 2025 | +4.9% | +0.7% | −4.2% | −4.1% | +4.1% | +5.4% | −0.3% | +5.5% | +3.4% | +1.9% | +2.6% | +0.3% |
| 2024 | +0.9% | +3.8% | +7.0% | −7.6% | +5.2% | +1.2% | +3.5% | −0.8% | +1.9% | −3.8% | +6.6% | −5.8% |
| 2023 | +5.7% | −3.9% | +0.7% | −1.3% | −2.9% | +6.5% | +4.0% | −1.0% | −2.3% | −2.6% | +8.2% | +6.9% |
| 2022 | −1.3% | −2.1% | +2.6% | −5.0% | +2.1% | −13.4% | +7.4% | −1.2% | −9.8% | +14.3% | +5.9% | −5.6% |
| 2021 | +4.8% | +2.8% | +6.8% | +2.5% | +3.1% | +0.2% | −0.6% | +2.6% | −4.7% | +2.0% | −1.4% | +6.8% |
| 2020 | −2.2% | −10.7% | −21.4% | +13.7% | +4.2% | +2.0% | +4.3% | +5.3% | −2.7% | −1.4% | +14.6% | +4.3% |
| 2019 | — | — | — | — | — | — | +1.0% | −4.6% | +4.3% | +2.1% | +3.3% | +3.8% |
PXTNX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 13.77%
- 3-year Sharpe ratio: 1.29 (vs 4.5% risk-free rate)
- Best month: +8.24% (Nov 2023)
- Worst month: −7.60% (Apr 2024)
PXTNX Fund Flows
Monthly money in and out of PIMCO RAE PLUS Fund, from SEC Form N-PORT.
- 12-month net flow: −$30.9M
- 12-month gross sales (incl. reinvestments): $223.7M
- Sales ÷ redemptions: 0.88×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $43.9M | $23.2M | $20.7M |
| May 2026 | $8.4M | $16.8M | −$8.4M |
| Apr 2026 | $8.8M | $14.3M | −$5.5M |
| Mar 2026 | $20.3M | $20.4M | −$95K |
| Feb 2026 | $9.1M | $20.7M | −$11.6M |
| Jan 2026 | $8.9M | $15.7M | −$6.8M |
| Dec 2025 | $57.4M | $19.9M | $37.5M |
| Nov 2025 | $6.3M | $14.3M | −$8.0M |
| Oct 2025 | $38.7M | $52.0M | −$13.3M |
| Sep 2025 | $8.9M | $20.6M | −$11.7M |
| Aug 2025 | $5.8M | $15.7M | −$9.9M |
| Jul 2025 | $7.1M | $20.8M | −$13.7M |
PXTNX Assets Under Management
Net assets of PIMCO RAE PLUS Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $1.27B |
| 2026-03-31 | $1.15B |
| 2025-12-31 | $1.11B |
| 2025-09-30 | $1.09B |
| 2025-06-30 | $1.04B |
| 2025-03-31 | $1.08B |
| 2024-12-31 | $1.10B |
| 2024-09-30 | $1.17B |
| 2024-06-30 | $1.12B |
| 2024-03-31 | $1.13B |
| 2023-12-31 | $1.03B |
| 2023-09-30 | $960.93M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.